Biotechnology
Chondrial Therapeutics, LLC was formed to discover and develop orphan drugs for mitochondrial diseases. Our proprietary protein replacement platform is initially targeted at Friedreich's Ataxia, a disease afflicting more 15,000 people in the US and Europe. Our goal is to restore normal life to individuals with mitochondrial diseases. Our passion for solutions is only matched by our sense of urgency.